ArticleInternational journal of molecular sciences2014
The eTOX data-sharing project to advance in silico drug-induced toxicity prediction.
Article in International journal of molecular sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Large scale meta-analysis of preclinical toxicity data for target characterisation and hypotheses generation.PloS one · 2021Pooled it
- Medicinal Plants and Phytochemicals in Cardioprotection-Mechanistic Pathways and Translational Roadmap.Life (Basel, Switzerland) · 2026Review
- Mapping between clinical and preclinical terminologies: eTRANSAFE's Rosetta stone approach.Journal of biomedical semantics · 2025Article
- Using Jupyter Notebooks for re-training machine learning models.Journal of cheminformatics · 2022Article
- Article
- Increasing the Value of Data Within a Large Pharmaceutical Company Through In Silico Models.Methods in molecular biology (Clifton, N.J.) · 2022Article
- eTRANSAFE: Building a sustainable framework to share reproducible drug safety knowledge with the public domain.F1000Research · 2022Article
- Combined Pharmacophore and Grid-Independent Molecular Descriptors (GRIND) Analysis to Probe 3D Features of Inositol 1,4,5-Trisphosphate Receptor (IPInternational journal of molecular sciences · 2021Article
- Assessing the calibration in toxicological in vitro models with conformal prediction.Journal of cheminformatics · 2021Article
- The eTRANSAFE Project on Translational Safety Assessment through Integrative Knowledge Management: Achievements and Perspectives.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Open Targets Platform: supporting systematic drug-target identification and prioritisation.Nucleic acids research · 2021Article
- A property-response perspective on modern toxicity assessment and drug toxicity index (DTI).In silico pharmacology · 2021Review
- ELIXIR and Toxicology: a community in development.F1000Research · 2021Article
- Forced degradation studies of medroxyprogesterone acetate injectable suspensions (150 mg/ml) with implementation of HPLC, mass spectrometry, and QSAR techniques.Journal of pharmaceutical and biomedical analysis · 2020Article
- Rethinking drug design in the artificial intelligence era.Nature reviews. Drug discovery · 2020Review
- Review
- Generating Modeling Data From Repeat-Dose Toxicity Reports.Toxicological sciences : an official journal of the Society of Toxicology · 2018Article
- Development of an Infrastructure for the Prediction of Biological Endpoints in Industrial Environments. Lessons Learned at the eTOX Project.Frontiers in pharmacology · 2018Article
- Review
- Interactive Toxicogenomics: Gene set discovery, clustering and analysis in Toxygates.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug development, which follows numerous strict guidelines, are mostly not available in the public domain. These safety data are sometimes published as a condensed summary for the few compounds that reach the market, but the majority of studies are never made public and are often difficult to access in an automated way, even sometimes within the owning company itself. It is evident from many academic and industrial examples, that useful data mining and model development requires large and representative data sets and careful curation of the collected data. In 2010, under the auspices of the Innovative Medicines Initiative, the eTOX project started with the objective of extracting and sharing preclinical study data from paper or pdf archives of toxicology departments of the 13 participating pharmaceutical companies and using such data for establishing a detailed, well-curated database, which could then serve as source for read-across approaches (early assessment of the potential toxicity of a drug candidate by comparison of similar structure and/or effects) and training of predictive models. The paper describes the efforts undertaken to allow effective data sharing intellectual property (IP) protection and set up of adequate controlled vocabularies) and to establish the database (currently with over 4000 studies contributed by the pharma companies corresponding to more than 1400 compounds). In addition, the status of predictive models building and some specific features of the eTOX predictive system (eTOXsys) are presented as decision support knowledge-based tools for drug development process at an early stage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.